Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Loss and Comprehensive Loss

v3.22.4
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
EXPENSES      
Research and development $ 30,078 $ 23,966 $ 6,882
General and administrative 10,722 9,128 7,868
Total operating expenses 40,800 33,094 14,750
OTHER INCOME (EXPENSE)      
Interest income 199 17 69
Interest expense [note 9] (1,789)    
Other income/(expense) 40 (75) (49)
Total other income (expense) (1,550) (58) 20
Net loss and comprehensive loss $ (42,350) $ (33,152) $ (14,730)
Basic net loss per common share [note 1 and note 11 [i]] $ (4.00) $ (4.08) $ (5.42)
Diluted net loss per common share [note 1 and note 11 [i]] $ (4.00) $ (4.08) $ (5.42)
Shares used in computation of basic net loss per common share[note 1 and note 11 [i]] 10,593,034 8,119,836 2,718,909
Shares used in computation of Diluted net loss per common share[note 1 and note 11 [i]] 10,593,034 8,119,836 2,718,909